Clinical Trials
5 trialsNCT06611891 2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3 Recruiting
NCT06857305 2025-03-04
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Enrolling by invitation
NCT06612814 2024-09-25
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 3 Active not recruiting
NCT05301010 2023-02-27
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed